Aurora Cannabis Eases Patient Access to Medical Cannabis

TL;DR

Aurora Cannabis (ACB) is making it easier for patients to get their medical weed.

AI Summary

Aurora Cannabis Inc. announced on February 14, 2025, a news release detailing efforts to ease patient access to high-quality medical cannabis. The company, led by CEO Miguel Martin, is based in Edmonton, Alberta, Canada, and operates under the SIC code 2833 for medicinal chemicals and botanical products.

Why It Matters

This filing indicates Aurora Cannabis is focusing on improving patient access to its medical products, which could impact its market share and revenue in the medical cannabis sector.

Risk Assessment

Risk Level: low — The filing is a routine report of a news release and does not contain significant financial or operational changes that would immediately impact risk.

Key Players & Entities

• Aurora Cannabis Inc. (company) — Registrant
• Miguel Martin (person) — Chief Executive Officer
• February 14, 2025 (date) — News Release Date
• Edmonton, Alberta (location) — Company Headquarters
• 2833 (industry_code) — Standard Industrial Classification

FAQ

From the Filing

0001279569-25-000151.txt : 20250218 0001279569-25-000151.hdr.sgml : 20250218 20250214190250 ACCESSION NUMBER: 0001279569-25-000151 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250214 FILED AS OF DATE: 20250218 DATE AS OF CHANGE: 20250214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 25631878 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News Release dated February 14, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: February 14, 2025 EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 14, 2025 Exhibit 99.1 Breaking Down Barriers: Aurora Cannabis Eases Patient Access to High Quality Medical Cannabis Products in Australia NASDAQ | TSX: ACB Largest Global Medical Cannabis Company Operating in Nationally Regulated Markets, Aurora Removes Concession Card Requirements to Access IndiMed Products in Australia EDMONTON, AB, Feb. 14, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, in conjunction with MedReleaf Australia, recently removed the concession card requirement for patients to access medical cannabis products under the Company's IndiMed brand. By removing this eligibility barrier, any patient in Australia can now be prescribed IndiMed products, providing greater patient access to high quality medical cannabis options. "This change to open up patient access to MedReleaf's IndiMed products reflects our dedication to supporting prescribers by creating more seamless and simplified prescribing options," said Andre Jerome, Executive Vice President, Global Business Development at Aurora. "It is a testament to our unmatched expertise in navigating international markets that we have the ability to quickly adapt and apply necessary change with ease, in order to meet patient demand in the rapidly growing medical cannabis market in Australia." IndiMed was first launched in Australia in 2021 as the very first concession product in the market. Over the years, the IndiMed portfolio has expanded to include oil, additional dried flower product and resin cartridges. Today, IndiMed flower product is consistently ranked in the top 10 most prescribed flowers for cannabis patients. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality, consistency and proudly meets all TGA-GMP standards. For further information about the company's offerings, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au. In addition, th